eb302eb9bf4446136c7a81a9839688de53241206
lrnassar
  Tue Sep 15 14:46:19 2020 -0700
Staging new clinGen composite on beta, and touching up desc page refs #24818

diff --git src/hg/makeDb/trackDb/human/clinGen.html src/hg/makeDb/trackDb/human/clinGen.html
index 57ee5dc..a5af4dc 100644
--- src/hg/makeDb/trackDb/human/clinGen.html
+++ src/hg/makeDb/trackDb/human/clinGen.html
@@ -41,39 +41,39 @@
 href="https://www.nlm.nih.gov/">National Center for Biotechnology Information (NCBI)</a> of the 
 <a target="_blank" href="https://www.nlm.nih.gov/">National Library of Medicine (NLM)</a>
 which distributes part of this information through its <a target="_blank"
 href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar</a> database.
 </p>
 
 <p>
 The available data tracks are:
 <ul>
 <li><b>Clinical Genome Resource Structural Variants (ClinGen Structural Variants)</b> -
 Shows curated copy number variants (CNVs) with sufficient pathogenic or benign evidence 
 as a mechanism for disease from the dbVar study 
 <a target="_blank" href="https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd45/">nstd45</a>
 (ClinGen Curated Dosage Sensitivity Map-obsoleted).
 </li>
-<li><b>Clinical Genome Resource Dosage Sensitivity Map Haploinsufficiency (ClinGen Haploinsufficiency) and -Triplosensitivity (ClinGen Triplosensitivity)</b> -
+<li><b>Clinical Genome Resource Dosage Sensitivity Map Haploinsufficiency (ClinGen Haploinsufficiency) and Triplosensitivity (ClinGen Triplosensitivity)</b> -
 Shows evidence supporting or refuting haploinsufficiency (loss) and triplosensitivity (gain) as 
 mechanisms for disease at gene-level and larger genomic regions.
 </li>
 </ul>
 </p>
 <p>
 A <b>rating system</b> is used to classify the <b>evidence</b> supporting or refuting dosage
- sensitivity for individual genes and regions, which takes in consideration the following criteria:
+ sensitivity for individual genes and regions, which takes into consideration the following criteria:
 number of causative mutations reported, patterns of inheritance, consistency of phenotype, evidence
 from large-scale case-control studies, mutational mechanisms, data from public genome variation 
 databases, and expert consensus opinion.
 </p>
 <p>
 The system is intended to be of a "dynamic nature", with regions being reevaluated periodically to 
 incorporate emerging evidence. The evidence collected is displayed within a publicly available 
 <a target="_blank" href="https://search.clinicalgenome.org/kb/gene-dosage">database</a>. 
 Evidence that haploinsufficiency or triplosensitivity of a gene is associated with a specific 
 phenotype will aid in the interpretive assessment of CNVs including that gene.
 </p>
 <h2>Display Conventions</h2>
 <p>
 <b>Structural Variants</b> are shaded according to variant type, 
 <b><font color="red">red</font color></b> for CNV loss, <b><font color="blue"> blue</font color></b>
@@ -88,31 +88,31 @@
 clinical significance (benign or pathogenic).
 </p>
 <p>
 <b>Dosage Scores</b> are used to classify the evidence of the supporting dosage sensitivity map:
 <dl>
 <dd><b>0</b> - no evidence available</dd>
 <dd><b>1</b> - little evidence for dosage pathogenicity</dd>
 <dd><b>2</b> - some evidence for dosage pathogenicity</dd>
 <dd><b>3</b> - sufficient evidence for dosage pathogenicity</dd>
 <dd><b>30</b> - gene associated with autosomal recessive phenotype</dd>
 <dd><b>40</b> - dosage sensitivity unlikely</dd>
 </dl>
 </p>
 For more information on the use of the scores see the ClinGen
 <a target="_blank" href="https://clinicalgenome.org/tools/cnv-webinar/faq/">FAQs</a>.
-Items are shaded according to dosage sensitivity type. <b><font color="red">red</font></b> for haploinsufficiency,
+Items are shaded according to dosage sensitivity type, <b><font color="red">red</font></b> for haploinsufficiency,
 <b><font color="blue">blue</font></b> for triplosensitivity, 
 and <B><font color="#a8a8a8">grey</font></b> for other evidence scores or 
 for genes/regions that have not been evaluated yet or no evidence is available. A light to dark
 gradient color is used according to the degree of supporting evidence.
 </p>
 <p>
 Mouseover on items shows the supporting evidence of dosage sensitivity and respective scores. All
 tracks can be filtered according to the supporting evidence of dosage sensitivity.
 </p>
 <p>
 These tracks are multi-view composite tracks that contain multiple data types (views). Each view 
 within a track has separate display controls, as described 
 <a href="../goldenPath/help/multiView.html">here</a>.
 </p>